# IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

> **NCT00368173** · PHASE2,PHASE3 · COMPLETED · sponsor: **Insmed Incorporated**

## Conditions studied

- Growth Hormone Insensitivity Syndrome (GHIS)
- Laron Syndrome

## Interventions

- **DRUG:** rhIGF-I/rhIGFBP-3

## Key facts

- **NCT ID:** NCT00368173
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368173, "IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00368173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*